- Home
- LLY
as 11-01-2025 4:23am EST
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
| Founded: | 1876 | Country: | United States |
| Employees: | N/A | City: | INDIANAPOLIS |
| Market Cap: | 716.8B | IPO Year: | N/A |
| Target Price: | $967.43 | AVG Volume (30 days): | 2.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 14 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 20.44 | EPS Growth: | 121.02 |
| 52 Week Low/High: | $623.78 - $935.63 | Next Earning Date: | 10-30-2025 |
| Revenue: | $59,419,800,000 | Revenue Growth: | 45.41% |
| Revenue Growth (this year): | 38.24% | Revenue Growth (next year): | 18.56% |
Stock Insider Trading Activity of Eli Lilly and Company (LLY)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| LILLY ENDOWMENT INC | LLY | 10% Owner | Oct 10 '25 | Sell | $862.85 | 3,658 | $3,157,722.23 | 94,536,510 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Oct 9 '25 | Sell | $852.81 | 10,602 | $9,038,055.41 | 94,536,510 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Oct 8 '25 | Sell | $852.10 | 101,420 | $86,234,873.84 | 94,536,510 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Oct 7 '25 | Sell | $848.01 | 26,795 | $22,722,401.16 | 94,536,510 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Oct 6 '25 | Sell | $852.07 | 161,183 | $137,041,656.51 | 94,536,510 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Oct 3 '25 | Sell | $834.94 | 192,404 | $161,220,401.35 | 94,536,510 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Oct 2 '25 | Sell | $826.99 | 112,596 | $92,503,361.30 | 94,536,510 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Oct 1 '25 | Sell | $804.45 | 351,015 | $284,653,464.64 | 94,536,510 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Sep 30 '25 | Sell | $764.75 | 113,694 | $86,793,273.90 | 94,536,510 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Sep 19 '25 | Sell | $763.76 | 23,665 | $18,058,643.25 | 94,536,510 |
Latest Eli Lilly and Company News
LLY Breaking Stock News: Dive into LLY Ticker-Specific Updates for Smart Investing
Simply Wall St.
5 hours ago
Why The Story Around Eli Lilly Is Evolving After Recent Analyst Updates and Company News
Investor's Business Daily
6 hours ago
Dow Jones Futures Loom For Tricky Market; Palantir, Robinhood Lead Earnings
Simply Wall St.
7 hours ago
Eli Lilly and Company Beat Revenue Forecasts By 9.5%: Here's What Analysts Are Forecasting Next
The Wall Street Journal
9 hours ago
Why Pfizer Can Still Prevail in the Obesity Fight With Novo Nordisk
Insider Monkey
a day ago
Eli Lilly (LLY) Would Be Up More If The Market Weren’t That Bad, Says Jim Cramer
Investor's Business Daily
a day ago
Dow Jones Futures: Palantir, Robinhood Lead Earnings After Market's Tricky October
Investor's Business Daily
a day ago
S&P 500 Giants JPMorgan, Eli Lilly Lead Five Stocks Near Buy Points
Yahoo Finance
a day ago
Nvidia's dizzying week of dealmaking
Compare LLY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LLY Eli Lilly and Company - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.